Zevalin Coding Brochure Fails To Include Risk Information, FDA Says
This article was originally published in The Pink Sheet Daily
Biogen Idec also cited by FDA's ad division for failing to note that the oncologic's effect on survival is unknown.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.
A National Institute for Health & Clinical Excellence analysis finds cost per quality-adjusted life year gained as high as $83,000.